Atai Beckley Inc.

NASDAQ:ATAI

Biotechnology

Healthcare
$7.35 -1.35%

-$0.06 today

Market cap
$2.72B
Beta
1.60
P/E (TTM)
-1.4
EPS (TTM)
-$2.93
52W Low $2.00High $6.75

Volume 0.00M

Average 5.68M

ATAI Effect of Forex Changes

Change in reported cash caused by exchange-rate movements on foreign-currency balances.

Atai Beckley Inc.NASDAQ: ATAI

Effect of Forex Changes · Q2 FY2026 · quarter ended Jun 2026

Effect of forex changes turns negative

Q2 FY2026 effect of forex changes was -$248K, compared with $206K a year earlier. Trailing-twelve-month effect of forex changes was -$2.31M.

Context

  • Effect of forex changes amounted to 2.8% of revenue in FY2025, down 114.7 pp from a year earlier.
  • Effect of forex changes increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly effect of forex changes holds near -$248K or moves back toward the trailing-twelve-month quarterly average of -$577.2K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$248K-10.1% QoQ
Last fiscal yearDec 2025
$116K-68.0% YoY
LTMJun 2026
-$2.31M-486.1% YoY
Effect of Forex Changes past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-220.4%——
1 year-68.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Effect of Forex Changes history

USD · from the cash flow

Latest · FY2025
116K USD
Year-over-year change
-68.0%

Effect of Forex Changes vs competitors

How ATAI compares with its peers on the latest reported figures

  • Peers report in different currencies, so effect of forex changes is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -486.1% is the lowest of 5, against a peer median of +3624.7%.
  • Effect of forex changes amounts to 51.6% of revenue for ATAI, versus a peer median of 0.0%.
ATAI Competitors
Effect of Forex Changes for ATAI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NKTRNektar TherapeuticsLTM Jun 2026$18.93M USD+118393.8%—34.7%
IMTXImmatics N.V.LTM Mar 2026€11.53M EUR+7148.8%+123.9%30.9%
ATAIAtai Beckley Inc.LTM Jun 2026$2.31M USD-486.1%—51.6%
AMLXAmylyx Pharmaceuticals, Inc.LTM Sep 2026$101K USD-111.3%——
DNTHDianthus Therapeutics, Inc.LTM Jun 2026$1K USD+100.6%—0.1%
RLAYRelay Therapeutics, Inc.LTM Jun 2026$0 USD——0.0%
ELVNEnliven Therapeutics, Inc.LTM Sep 2026$0 USD———
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026$0 USD——0.0%
INBXInhibrx Biosciences, Inc.LTM Mar 2026$0 USD——0.0%
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$0 USD———
SANASana Biotechnology, Inc.LTM Mar 2026$0 USD———
Peer median (excluding ATAI) —+3624.7%+123.9%0.0%

Competitors are the stored peer set for ATAI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(174.24M)(157.42M)(43.9M)(150.05M)(660.05M)
Depreciation & Amortization47K168K319K473K1.01M
Deferred Income Tax39.14M5.07M000
Stock-Based Compensation63.36M42.38M32.98M25.49M0
Change in Working Capital(7.6M)(3.34M)7.47M(9.2M)(6.48M)
Accounts Receivables00000
Inventory00000
Accounts Payables2.3M(3.03M)2.14M(1.87M)(1.7M)
Other Working Capital(9.9M)(301K)5.33M(7.33M)(4.78M)
Other Non-Cash Items16.06M8.67M(80.99M)50.85M562.84M
Operating Cash Flow(63.25M)(104.47M)(84.12M)(82.44M)(102.68M)
Capital Expenditures(1.13M)(1.02M)(590K)(95K)(901K)
Acquisitions (Net)(52.94M)0(443K)359K4.64M
Purchases of Investments(23.66M)(309.66M)(186.22M)(15M)(98.95M)
Sales of Investments(955K)226.83M139.47M82.01M9.05M
Other Investing Activities(2.6M)(3.25M)(5.84M)(8.1M)(13M)
Investing Cash Flow(81.28M)(86.85M)(53.3M)59.17M(109.13M)
Debt Repayment1.59M15M05M7.71M
Common Stock Issued409.88M00535K283.43M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities2.42M5.19M(8.36M)(161K)(21.66M)
Financing Cash Flow409.86M20.79M(8.36M)5.37M269.48M
Effect of Forex Changes(320K)(1.12M)189K362K116K
Net Change in Cash265.02M(171.65M)(145.58M)(17.53M)57.8M
Free Cash Flow(64.37M)(105.49M)(84.71M)(82.53M)(103.58M)

Atai Beckley Inc.

NASDAQ:ATAI

Intrinsic Alpha fair value

Locked

Current Price

$7.35

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.